Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Cash from Financing Activities (2022 - 2026)

HeartSciences' Cash from Financing Activities history spans 5 years, with the latest figure at $2.9 million for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 1529.6% year-over-year to $2.9 million; the TTM value through Jan 2026 reached $8.2 million, up 172.14%, while the annual FY2025 figure was $2.7 million, 73.57% down from the prior year.
  • Cash from Financing Activities reached $2.9 million in Q1 2026 per HSCS's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $9.1 million in Q1 2024 to a low of -$121522.0 in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $1.8 million, with a median of $782374.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: plummeted 106.32% in 2023, then surged 7610.17% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$116392.0 in 2022, then skyrocketed by 542.15% to $514629.0 in 2023, then skyrocketed by 269.53% to $1.9 million in 2024, then decreased by 20.66% to $1.5 million in 2025, then skyrocketed by 94.6% to $2.9 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Cash from Financing Activities are $2.9 million (Q1 2026), $1.5 million (Q4 2025), and $3.6 million (Q3 2025).